Corporate Year-End Update
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
17 December 2024
IBX Corporate Year-End Update
IBX General Meeting secures 2nd Tranche of $3M funding led by CPS Capital
Collaboration with Siemens for support of MagSense® clinical studies resumed
MELBOURNE – Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare through the early
detection of cancer, is pleased to provide this year-end business update for shareholders and the markets.
At the 9 December 2024 General Meeting, shareholders approved the second Tranche of the highly successful
and oversubscribed capital raise that was announced on October 10th. The company has now received Tranche
2 of the placement led by CPS Capital ($2.824m after costs). These funds will be used to advance the clinical
development of the Company’s MagSense® molecular MRI imaging technology, as well as general operating
expenses.
“We are ending the year with a shift in momentum having just raised $3M,” said Executive Chairman Bob Proulx.
We now have a financial runway to get back on track to advance our cancer detection technology platform.”
Positive Outlook for 2025
With working capital now in hand, the Company will now take steps to prioritize the clinical development of the
MagSense® HER2 imaging agent. The Company has already established a core team of consultants and
advisors, including the appointment of Dr. Susan Harvey for Medical Affairs, and aims to achieve filing an
Investigational New Drug (IND) application with the FDA as soon as possible in 2025.
Additionally, at the recent Radiological Society of North America (RSNA) meeting, the Company met with and
confirmed that it would continue to have the collaboration of Siemens MRI experts to support the Phase 2 study.
A key element of the Phase 2 study is to optimize the imaging protocol, and the collaboration with Siemens is
aimed at ensuring the study achieves the best possible imaging results. “It’s gratifying to know Siemens continues
to be supportive of our programs,” said Ward Detwiler, Imagion’s Chief Business Officer. “Having the collaboration
of one of the world’s leading MRI companies shows our MagSense® molecular MRI technology has the potential
to bring value to the healthcare markets and expand how MRI is used in cancer diagnosis.”
Beginning in January the Company will be focused on the following key activities to achieve filing an IND as soon
as possible with the aim of initiating the Phase 2 study in the second half of 2025, assuming funding is in place.
Commencing manufacturing of a new batch of the MagSense® HER2 imaging agent;
Selecting the lead investigators for the Phase 2 study;
Finalizing the study design; and
Initiating site selection through a Contract Research Organization (CRO).
For additional information related to the planned Phase 2 study and the clinical utility of the MagSense® HER2
imaging agent please see the Company’s November 14th Corporate Update.
JP Morgan Healthcare Conference
Executive Chairman, Bob Proulx will be attending the JP Morgan Healthcare Conference in San Francisco from
13 – 15 January 2025. This is the world’s largest healthcare-based investor conference. Interested investors
can request a meeting by sending a message to info@imagionbio.com
Authorisation & Additional Information
This announcement was authorised by the Board of Imagion Biosystems Limited.
Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Level 4, 100 Albert Road, South Melbourne Vic 3205 Australia
http://www.imagionbiosystems.com/ | investor@imagionbio.com
ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology.
Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier
and with higher specificity than is currently possible.
For more information, visit https://imagionbiosystems.com/investor-hub/
Media & Investor Relations:
Email: info@imagionbio.com
AU: +61 3 9692 7222
Share your feedback
Discover